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Expression of the G protein-coupled estrogen
receptor (GPER) in endometriosis: a tissue
microarray study
Nicolas Samartzis1†, Eleftherios P Samartzis1†, Aurelia Noske2, André Fedier1, Konstantin J Dedes1, Rosmarie Caduff2,
Daniel Fink1 and Patrick Imesch1*
Abstract
Background: The G protein-coupled estrogen receptor (GPER) is thought to be involved in non-genomic estrogen
responses as well as processes such as cell proliferation and migration. In this study, we analyzed GPER expression
patterns from endometriosis samples and normal endometrial tissue samples and compared these expression
profiles to those of the classical sex hormone receptors.
Methods: A tissue microarray, which included 74 samples from different types of endometriosis (27 ovarian, 19
peritoneal and 28 deep-infiltrating) and 30 samples from normal endometrial tissue, was used to compare the
expression levels of the GPER, estrogen receptor (ER)-alpha, ER-beta and progesterone receptor (PR). The
immunoreactive score (IRS) was calculated separately for epithelium and stroma as the product of the staining
intensity and the percentage of positive cells. The expression levels of the hormonal receptors were dichotomized
into low (IRS< 6) and high (IRS>=6) expression groups.
Results: The mean epithelial IRS (+/−standard deviation, range) of cytoplasmic GPER expression was 1.2
(+/−1.7, 0–4) in normal endometrium and 5.1 (+/−3.5, 0–12) in endometriosis (p< 0.001), of nuclear GPER 6.4
(+/−2.6, 0–12) and 6.8 (+/−2.9, 2–12; p= 0.71), of ER-alpha 10.6 (+/−2.4, 3–12) and 9.8 (+/−3.0, 2–12; p= 0.26),
of ER-beta 2.4 (+/−2.2; 0–8) and 5.6 (+/−2.6; 0–10; p< 0.001), and of PR 11.5 (+/−1.7; 3–12) and 8.1 (+/−4.5; 0–12;
p< 0.001), respectively. The mean stromal IRS of nuclear GPER expression was 7.7 (+/−3.0; 2–12) in endometrium
and 10.8 (+/−1.7; 6–12) in endometriosis (p< 0.001), of ER-alpha 8.7 (+/−3.1; 2–12) and 10.6 (+/−2.4; 2–12; p= 0.001),
of ER-beta 1.8 (+/−2.0; 0–8) and 5.4 (+/−2.5; 0–10; p< 0.001), and of PR 11.7 (+/−0.9; 8–12) and 10.9 (+/−2.0; 3–12;
p= 0.044), respectively. Cytoplasmic GPER expression was not detectable in the stroma of endometrium and
endometriosis. The observed frequency of high epithelial cytoplasmic GPER expression levels was 50% (n = 30/60) in
the endometriosis and none (0/30) in the normal endometrium samples (p< 0.001). High epithelial cytoplasmic
GPER expression levels were more frequent in endometriomas (14/20, 70%; p= 0.01), as compared to peritoneal
(9/18, 50%) or deep-infiltrating endometriotic lesions (7/22, 31.8%). The frequency of high stromal nuclear GPER
expression levels was 100% (n = 74/74) in endometriosis and 76.7% (n = 23/30) in normal endometrium (p< 0.001).
The frequency of high epithelial nuclear GPER expression levels did not differ between endometriosis and normal
endometrium.
Conclusions: The present data indicate a unique GPER expression pattern in endometriosis, especially in
endometriomas as compared to the normal endometrium. The overexpression of GPER in endometriotic lesions
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suggests a potential role for GPER in the hormonal regulation of endometriosis, which should be taken into
consideration for future hormonal treatment strategies.
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Background
Endometriosis is a common, benign inflammatory disease
defined by the presence of endometrial cells outside of the
uterine cavity [1]. This disease affects 5 to 10% of women
within reproductive age and is clinically characterized by
chronic pelvic pain, dysmenorrhea, dyspareunia and
infertility [2-4].
Although the exact mechanism of endometriosis patho-
genesis has not yet been fully elucidated, estrogens are
known to play a key role in this process. Therefore, cur-
rently available medical treatment options employ various
mechanisms to target the estrogen pathway. The classic
biological effects associated with estrogens are mediated
by the estrogen receptors (ERs) ER-alpha and ER-beta.
Recently, the G protein-coupled estrogen receptor
(GPER), which is also known as the G protein-
coupled receptor 30 (GPR30), has been described as a
novel ER that exhibits a high-affinity binding site for
estrogens [5]. GPER is a seven-transmembrane recep-
tor that is thought to be part of the rapid, non-
genomic estrogen responses that can, in contrast to
the classic or genomic modes of ER activity, occur
within minutes [6,7].
The GPER-mediated activity of estrogen is involved in
multiple physiological intracellular processes, such as
phosphatidylinositol-3-OH kinase activation, calcium
mobilization, cyclic AMP production and extracellular sig-
nal-dependent kinase activation [8,9]. In cancer cells,
GPER may enhance proliferative processes mediated by
the actions of estrogens and tamoxifen [7,10].
Bulun et al. demonstrated that the levels of ER-alpha,
ER-beta and progesterone-receptor (PR) are markedly
different in endometrial cells as compared to endometri-
osis-derived stromal cells [11]. While the expression
levels of ER-beta were observed to be higher in endome-
triotic stromal cells as compared with endometrial stro-
mal cells, the expression levels of ER-alpha and PR were
reported to be higher in endometrial stromal cells.
Moreover, GPER expression has not been studied in
endometriotic cells to date. As estrogen activity plays a
key role in the development of endometriosis, an inves-
tigation into GPER expression in endometriotic tissue is
warranted. Therefore, the aim of this study was to deter-
mine the level of GPER expression in endometriotic
cells and to compare this expression level with that of
the classical sex receptors ER-alpha, ER-beta and PR.
Methods
Patient selection
This study was approved by the local ethics committee
(ref. number KEK-ZH-NR 2010-0174/0). Patients were
retrospectively included in this study after receiving a bi-
opsy-proven diagnosis of endometriosis. Additional in-
clusion criteria included the availability of adequate
tissue quantity, exclusively proliferative cell cycle status
and a lack of supplemental hormonal intake (neither
GnRH analogs nor oral contraceptives). All specimens
were paraffin-embedded in tissue blocks, and the histo-
logical diagnosis of endometriosis was conducted be-
tween 2000 and 2010 at the Institute of Pathology of the
University Hospital in Zurich. These diagnoses were
reviewed by a gynecological pathologist (R.C.). In accord-
ance with the inclusion criteria of the study, 71 patients
with endometriosis and 30 control patients with normal
endometria and no diagnosis of endometriosis were
identified. The control cases included patients who had
undergone hysterectomies for benign conditions other
than diseases affecting the endometrium or endometri-
osis. A total of 74 endometriotic specimens (three
patients each provided two separate samples of endome-
triotic tissue from distinct localizations) and 30 normal
endometrial specimens were examined in the study.
Histological specimens were obtained from patients with
ovarian endometriomas (n = 27), peritoneal endometri-
osis (n = 19) and deep-infiltrating endometriosis (n = 28).
Tissue microarray construction
A tissue microarray (TMA) was constructed using a semi-
automatic tissue arrayer (Beecher Instruments, Woodland,
USA), as previously described [12,13]. Tissue areas exhibit-
ing endometriosis were marked on hematoxylin/eosin-
stained sections. Cylindrical cores of 0.6 mm in diameter
were punched out of the corresponding paraffin-embedded
blocks and inserted into a recipient block. Two different
spots from each patient sample were punched out.
Immunohistochemistry
TMA sections (2.5-μm thick) were transferred to glass
slides for the immunohistochemical (IHC) analysis, accord-
ing to the Ventana automated protocols. The following
antibodies were used for IHC analysis: monoclonal rabbit
antibodies against ER-alpha (prediluted and obtained from
Ventana Medical System Inc., clone SP1), monoclonal
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mouse antibodies against ER-beta (diluted at 1:150 and
obtained from Gene Tex, Inc., clone 14 C8), monoclonal
mouse antibodies against PR (prediluted and obtained from
Ventana Medical System, Inc., clone 1A6) and polyclonal
rabbit antibodies against GPER (diluted at 1:50 and
obtained from Abcam Limited, code ab39742). Normal
breast tissue and breast cancer tissue served as positive
controls for GPER expression. Normal endometrial tissue
was used as a positive control for ER and PR expression.
Negative controls were performed by omitting the primary
antibody.
Scoring
The TMA was scored independently by two observers
(A.N. and N.S.) who were blinded to the clinicopatholo-
gical information associated with the samples. Two tissue
cores from each individual case were evaluated. The
expression of ER (alpha and beta), PR, and GPER was
evaluated separately for epithelium and stroma according
to the percentage of positive cells and the intensity of
the staining. The percentage of positive cells was scored
using the following numeric system: 0 (0% positive cells);
1 (<10%); 2 (11-50%); 3 (51-80%); and 4 (>80%). The
staining intensity was scored as either 0 (negative), 1
(weak), 2 (moderate) or 3 (strong). For the immunoreac-
tive score (IRS) [14], the percentage of positive cells and
the staining intensity were multiplied, which produced a
value for the IRS between 0 and 12. To separate cases
with a weak or strong immunoreaction, we used a
median nuclear GPER IRS of 6 as the cutoff point for
dichotomization. The same cutoff value was used for the
other receptors, and this created a “high expression”
group (IRS of 6 or more) and a “low expression” group
(IRS less than 6) [15].
Statistical analysis
The results are presented as the absolute numbers and
percentages and as the mean values, standard deviations
and ranges. P-values ≤0.05 were considered statistically
significant if not indicated differently. SPSS (version 19,
SPSS Inc., Chicago, IL) was utilized for the statistical
analysis. Non-parametric tests were used to compare the
IRS values between the different sample groups. There-
fore, a Wilcoxon rank-sum test was used to compare the
IRS in endometrium and endometriosis. The significance
levels for the endometrium and the subgroups of endo-
metriosis were assessed by a Kruskal-Wallis one-way
analysis of variance followed post-hoc by a pairwise Wil-
coxon rank-sum test. In these cases, a Bonferroni correc-
tion (α’= α/6) was performed and p-values were only
considered significant if p≤ 0.0083. Frequencies of low
and high expression levels were analyzed by an exact
2-sided Pearson chi-square test. Bivariate correlation
analysis was done with Spearman’s rho.
Results
Patients’ clinical characteristics
The mean age (±standard deviation, range) of the patients
in the endometriosis cohort was 33.9 (±5.8, 19–48) years,
as compared to 39.5 (±3.3, 29–44) years for patients in the
control group. Regarding the different endometriosis sub-
types the mean age was 35.2 (±6.9, 19–48) years for
patients with ovarian endometriosis, 31.3 (±4.0, 25–38)
years for patients with peritoneal endometriosis, and 34.5
(±5.4, 25–42) years for patients with deep-infiltrating endo-
metriosis. Endometriosis staging, according to the classifi-
cations of the American Society for Reproductive Medicine
[16], had been assigned as follows: stage I for 5/74 cases
(6.8%); stage II for 7/74 cases (9.5%); stage III for 15/74
cases (20.3%); stage IV for 34/74 cases (45.9%); and N/A for
13/74 (17.5%) cases. The patients’ body mass indexes
(BMIs) were available in 51/104 (49%) of the cases, and
these exhibited mean values of 22.0 (±5.0, 16–40) kg/m2
for patients in the endometrioma group, 24.2 (±7.5, 20–45)
kg/m2 for the peritoneal endometriosis group, 25.1 (±10.0,
19–47) kg/m2 for the deep-infiltrating endometriosis group
and 23.5 (±3.7, 16–30) kg/m2 for the control group.
Immunohistochemical analysis
Immunohistochemical (IHC) staining of GPER, ER-alpha,
ER-beta, and PR was evaluable in 86.5% (n= 90/104),
89.4% (93/104), 91.3% (95/104), and 86.5% (90/104) of all
cases for the epithelial parts and in 100% (n=104/104),
96.2% (n=100/104), 97.1% (n= 101/104), and 98.1%
(n=102/104) for the stromal parts, respectively. The
remaining cases were not evaluable mainly due to a lack of
adequate tissue (either epithelial, stromal, or both) from
the respective samples. We observed (in contrast to find-
ings regarding ER/PR expression) nuclear and cytoplasmic
expression of GPER in the epithelium of endometriotic
lesions. As a result, both of these staining patterns were
analyzed separately. Membrane-specific staining of GPER
was not detectable in the endometrial or the endometriotic
tissue samples. The mean epithelial IRS (+/−standard devi-
ation, range) of cytoplasmic GPER expression was 1.2
(+/−1.7, 0–4) in normal endometrium and higher with 5.1
(+/−3.5, 0–12) in endometriosis (p< 0.001). The mean epi-
thelial IRS of nuclear GPER expression was comparable
with 6.4 (+/−2.6, 0–12) in the endometrium and 6.8
(+/−2.9, 2–12) in endometriosis (p=0.71). ER-alpha
showed a mean epithelial IRS of 10.6 (+/−2.4, 3–12) in the
endometrium and of 9.8 (+/−3.0, 2–12) in endometriosis
(p=0.26). The mean epithelial IRS of ER-beta was 2.4
(+/−2.2; 0–8) in endometrium and higher (p< 0.001) in
endometriosis with 5.6 (+/−2.6; 0–10). The mean epithelial
IRS of PR was higher (p< 0.001) in the endometrium with
11.5 (+/−1.7; 3–12) than in endometriosis 8.1 (+/−4.5;
0–12). The mean stromal IRS of nuclear GPER expression
was 7.7 (+/−3.0; 2–12) in normal endometrium and 10.8
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(+/−1.7; 6–12) in endometriosis (p< 0.001). Cytoplasmic
GPER expression was not detectable in the stroma of
endometrium and endometriosis. The mean stromal IRS
of ER-alpha was 8.7 (+/−3.1; 2–12) in normal endomet-
rium and 10.6 (+/−2.4; 2–12) in endometriosis (p=0.001).
The mean stromal IRS of ER-beta was 1.8 (+/−2.0; 0–8) in
endometrium and higher (p< 0.001) in endometriosis with
5.4 (+/−2.5; 0–10) for ER-beta. The mean stromal IRS of
PR was 11.7 (+/−0.9; 8–12) in normal endometrium and
10.9 (+/−2.0; 3–12) in endometriosis (p=0.044). The mean
IRS values for all subtypes of endometriosis are reported in
Table 1 and represented as charts in Figure 1. Representa-
tive histological images are depicted in Figure 2 and more
detailed histological sections for GPER are shown in
Figure 3 including positive control tissue samples.
Frequencies of low and high expression groups
Following dichotomization in low and high expression
groups, we analyzed the frequency of the cases. High epi-
thelial expression of cytoplasmic GPER was significantly
more frequent (p< 0.001) in endometriotic tissues (n= 30/
60, 50%) than in eutopic endometrial tissues (n= 0/30). In
regards of the different endometriosis subtypes, high cyto-
plasmic GPER expression levels were more frequent in
endometriomas (14/20, 70%; p=0.01), as compared to
peritoneal (9/18, 50%) or deep-infiltrating endometriotic
lesions (7/22, 31.8%). However, no significant differences
between endometriotic and eutopic endometrial samples
were observed in regards to the nuclear expression of
GPER in the epithelium. In the stroma the frequency of
high nuclear GPER expression levels was 100% (n=74/74)
in endometriosis and 76.7% (n=23/30) in normal endo-
metrium (p< 0.001). High ER-beta expression levels were
more frequent in endometriosis than in eutopic
endometrial cells (p< 0.001) for both, stroma and epithe-
lium. Low PR expression levels were seen more frequently
in the epithelium of endometriosis (p=0.005) but not in the
stroma (p=0.6). The differences in the epithelial PR expres-
sion levels were mainly associated with the lower expression
ovarian endometriosis, as shown in Figure 1. More cases of
low epithelial expression levels of ER-alpha and PR (21.7%
and 61.9%, respectively) were observed in samples of ovar-
ian endometriosis, as compared with those of peritoneal
endometriosis (0% and 5.9%, respectively) and deep-infil-
trating endometriosis (4.3% and 18.2%, respectively; p-value
of 0.02 and <0.001). All expression level frequencies for
cytoplasmic and nuclear GPER, ER-alpha, ER-beta and PR
in epithelium and stroma of endometrium and endometri-
osis including the endometriosis subtypes are reported in
detail in Tables 2, 3, 4 and 5.
Correlations of the GPER expression with the classic
sex-hormone receptors
The relationship between GPER expression and the expres-
sion of ER-alpha, ER-beta and PR was evaluated using
Spearman’s correlation coefficients (CC). Significant, posi-
tive correlations were observed between nuclear and cyto-
plasmic GPER expression and nuclear ER-beta expression
in epithelial cells (CC=0.221 and 0.569, p-values of 0.037
and <0.001, respectively), as well as between the stromal
expression of GPER and the stromal expression of ER-beta
(CC=0.703, p< 0.001). Cytoplasmic GPER expression
levels in epithelial cells negatively correlated with epithelial
PR expression levels (CC=−0.290, p=0.006), and stromal
nuclear GPER expression levels negatively correlated with
stromal ER-alpha expression levels (CC=−0.511, p< 0.001).
The ER-alpha expression levels correlated with the PR
expression levels in both the epithelial and stromal
Table 1 Mean immunoreactivity scores of the expression of GPER, ER alpha, ER beta and PR in the epithelium and
stroma of normal endometrium and different endometriosis types
Normal
Endometrium
Ovarian
Endometriosis
Peritoneal
Endometriosis
Deep-Infiltrating
Endometriosis
Epithelium
GPER cyt 1.2 (±1.7, 0–4) 6.5 (±3.5, 0–12) 5.0 (±3.7, 0–10) 4.0 (±2.8, 0–8)
GPER nuc 6.4 (±2.6, 0–12) 6.9 (±1.8, 3–8) 8.5 (±3.8, 2–12) 5.4 (±2.2, 2–12)
ER alpha 10.6 (±2.4, 3–12) 8.6 (±3.5, 2–12) 11.4 (±1.6, 6–12) 9.8 (±2.7, 3–12)
ER beta 2.4 (±2.2, 0–8) 5.4 (±2.6, 0–10) 7.4 (±1.5, 4–10) 4.5 (±2.5, 0–8)
PR 11.5 (±1.7, 3–12) 4.6 (±4.3, 0–12) 10.9 (±2.4, 3–12) 9.2 (±3.7, 2–12)
Stroma
GPER nuc 7.7 (±3.0, 2–12) 10.7 (±1.6, 8–12) 11.7 (±0.8, 9–12) 10.1 (±1.9, 6–12)
ER alpha 8.7 (±3.1, 2–12) 10.6 (±2.1, 6–12) 11.3 (±1.6, 6–12) 10.1 (±3.0, 2–12)
ER beta 1.8 (±2.0, 0–8) 5.4 (±2.3, 0–10) 7.6 (±1.3, 4–10) 3.9 (±2.3, 0–8)
PR 11.7 (±0.9, 8–12) 11 (±1.4, 8–12) 10.4 (±2.5, 3–12) 11 (±2.1, 4–12)
Values are represented as mean immunoreactivity scores (IRS) (±standard deviation, range). GPER G protein-coupled estrogen receptor (cyt cytoplasmic, nuc nuclear
staining), ER estrogen receptor, PR progesterone receptor. No cytoplasmic GPER expression was detected in the stroma of endometrium and endometriosis.
T4 T5
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compartments, as demonstrated by CC values of 0.448 and
0.259 (p-values <0.001 and 0.009), respectively.
Discussion
Endometriosis is considered an estrogen-dependent dis-
ease, and most current medical therapeutic options target
aspects of estrogen stimulus [1-4]. The classic estrogen
signaling pathway is thought to be mediated by two
nuclear estrogen receptors (ER-alpha and ER-beta), which
are encoded by different genes [11,17]. These ligand-
activated receptors act as transcription factors to mediate
a number of estrogen-dependent responses, and the rela-
tive abundance of these two receptors differs between
eutopic and ectopic endometrial tissues.
In the present study, we observed different expression
levels for the established ERs and the PR in endometriotic
Figure 1 Immunoreactivity Scores. Mean Immunoreactivity Scores (IRS) and 95% confidence intervals (error bars) for the expression of the (A)
cytoplasmic expression of the G protein-coupled estrogen receptor (GPER cytoplasmic), the (B) nuclear expression of the G protein-coupled
estrogen receptor (GPER nuclear), the (C) estrogen receptor alpha (ER-alpha), the (D) estrogen receptor beta (ER-beta), and the (E) progesterone
receptor (PR) in the epithelium of normal endometrium (normal EM), ovarian endometriosis (ovarian ES), peritoneal endometriosis (peritoneal ES)
and deep-infiltrating endometriosis (deep ES), as well as (F-J) the same receptors in the stroma of the mentioned tissues. Stromal cells did not
show cytoplasmic GPER expression in endometrium and endometriosis and hence no corresponding chart is represented in this figure.
Significance (*) was considered if p≤ 0.0083 in the pairwise analysis according to a Bonferroni correction (α’= α/6). Highly significant values
(p≤ 0.0016) are marked with (**).
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tissue; there was a relative upregulation in the expression
of ER-beta in endometriotic epithelium and stroma, as well
as a downregulation in the epithelial expression of PR.
This result is in line with several studies that have reported
elevated levels of ER-beta and postulated a functional pro-
gesterone resistance in endometriotic tissues in ectopic
endometrial tissue [11].
In addition to its relatively slow genomic mechanism
of action, estrogen can also act via a more rapid, non-
genomic mechanism. In recent years, the GPER has
been shown to mediate estrogen signaling in various cell
types and is involved in the non-genomic estrogen
signaling pathway [18].
In the present study, we demonstrated that GPER
expression is detectable in the cytoplasm and the nucleus
of endometrial and endometriotic cells. Epithelial and stro-
mal endometrial and endometriotic cells exhibited a dis-
tinct expression pattern of GPER. Cytoplasmic GPER
expression was significantly higher in the epithelium of all
types of endometriosis (peritoneal, ovarian and deep infil-
trating endometriotic tissues) compared to normal endo-
metrium. Interestingly, we observed an equal distribution
of GPER in the nuclei of epithelial eutopic and ectopic
endometrial cells, including the various endometriotic tis-
sue types examined. In contrast to the epithelium, cyto-
plasmic GPER expression was not detectable in stromal
Figure 2 Representative histological tissue samples. Representative tissue samples of a normal endometrium (EM normal) microarray core
(A1 – A5), an ovarian endometriosis (ES ovarian) tissue core (B1 – B5), a peritoneal endometriosis (ES peritoneal) tissue core (C1 – C5) and a
deep-infiltrating endometriosis (ES deep) tissue core (D1 – D5). The samples were stained with hematoxylin/eosin (HE) (A1, B1, C1, D1), as well as
by immunohistochemistry to detect the G protein-coupled estrogen receptor (GPER) (A2, B2, C2, D2), the estrogen receptor alpha (ER-alpha) (A3,
B3, C3, D3), the estrogen receptor beta (ER-beta) (A4, B4, C4, D4) and the progesterone receptor (PR) (A5, B5, C5, D5) expression;
Magnification × 200.
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endometrial and endometriotic cells. Nuclear cytoplasmic
GPER expression was significantly increased in the stroma
of endometriosis compared to normal endometrial stroma.
To date, the localization of GPER has been a subject of
debate. Some authors have argued that GPER is localized
to the plasma membrane, while others have suggested that
the receptor is located within the endoplasmic reticulum,
as indicated by microscopy studies using fluorescence-
labeled 17-alpha-substituted estrogen derivatives [8,19-22].
Additionally, in a recent study, the nuclear localization of
GPER was demonstrated in fibroblasts, indicating that
Figure 3 Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis, in normal endometrium and in the positive
control. (A-C) Expression of the G protein-coupled estrogen receptor (GPER) in ovarian endometriosis with strong cytoplasmic and partial nuclear
expression in the epithelium and strong nuclear expression in the stroma (A, 200×; B, 400×), compared to normal endometrium with positive
nuclear and lack of cytoplasmic GPER expression (C, 200×). (D-E) GPER expression from breast carcinoma as a positive control with (D, 200×)
strong cytoplasmic and negative nuclear GPER expression, as well as with (E, 200×) weak cytoplasmic and strong nuclear GPER expression.
Table 2 Frequencies of the epithelial expression levels of
GPER (nuclear and cytoplasmic) and the classical sex
hormone receptors in normal endometrium and
endometriosis
Receptor Expression level Endometrium Endometriosis p-value
GPER cyt High 0/30 30/60 (50%) <0.001
Low 30/30 (100%) 30/60 (50%)
GPER nuc High 19/30 (63.3%) 42/60 (70%) 0.6
Low 11/30 (36.7%) 18/60 (30%)
ER-alpha High 28/30 (93.3%) 57/63 (90.5%) 0.7
Low 2/30 (6.7%) 6/63 (9.5%)
ER-beta High 3/30 (10%) 35/65 (53.8%) <0.001
Low 27/30 (90%) 30/65 (46.2%)
PR High 29/30 (96.7%) 42/60 (70%) 0.005
Low 1/30 (3.3%) 18/60 (30%)
GPER G protein-coupled estrogen receptor (cyt cytoplasmic, nuc nuclear
staining), ER estrogen receptor, PR progesterone receptor. P-Values were
calculated by an exact 2-sided Pearson chi-square test; p≤ 0.05 was considered
as statistically significant and is reported in bold type.
Table 3 Frequencies of the stromal expression levels of
GPER (nuclear and cytoplasmic) and the classical sex
hormone receptors in normal endometrium and
endometriosis
Receptor Expression level Endometrium Endometriosis p-value
GPER nuc High 23/30 (76.7%) 74/74 (100%) <0.001
Low 7/30 (23.3%) 0/74
ER-alpha High 25/30 (83.3%) 68/70 (97.1%) 0.02
Low 5/30 (16.7%) 2/70 (2.9%)
ER-beta High 2/30 (6.7%) 35/71 (49.3%) <0.001
Low 28/30 (93.3%) 36/71 (50.7%)
PR High 30/30 (100%) 70/72 (97.2%) 0.6
Low 0/30 2/72 (2.8%)
GPER G protein-coupled estrogen receptor (nuc nuclear staining); ER estrogen
receptor; PR progesterone receptor. No cytoplasmic GPER expression was
detected in the stroma of endometrium and endometriosis. P-Values were
calculated by an exact 2-sided Pearson chi-square test; p≤ 0.05 was considered
as statistically significant and is reported in bold type.
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GPER also mediates a nuclear signaling pathway [23].
Moreover, two recent studies demonstrated nuclear GPER
expression in eutopic endometrial cells [24,25].
One limitation of the current study was the sole evalu-
ation of the level of functional protein during the prolif-
erative phase of the menstrual cycle. Further evaluations
are required to clarify whether there are different
expression levels of mRNA and functional protein dur-
ing the menstrual cycle.
Dennis et al. observed that the GPER-specific antagonist
G15 was capable of partially inhibiting the estrogen-
dependent proliferation of uterine epithelia [26] and con-
cluded that GPER partially mediates the estrogen-induced
proliferative response of the uterine epithelium. In this
context, the upregulation of GPER expression in endome-
triotic lesions could play a crucial role in the pathogenesis
of endometriosis, especially considering that ligand stimu-
lation of GPER can activate multiple signaling pathways,
including the adenyl cyclase, Src and sphingosine kinase
pathways [5,27]. Recent studies have demonstrated the
transactivation of the epidermal growth factor receptor
(EGFR) following activation by GPER [28], and EGFR
activation can control multiple downstream events, such
as the activation of the mitogen-activated protein
kinases (MAPKs) and phosphatidylinositol 3-kinases
(PI3Ks). MAPKs and PI3Ks are involved in numerous
cytosolic pathways that, when activated, often lead to
cell proliferation, migration and adhesion, which are im-
portant steps in the pathogenesis of endometriosis [27].
Knowledge about the expression of GPER is therefore of
special interest for better understanding of regulative
mechanisms in the pathogenesis of endometriosis.
Conclusions
The aim of the present study was to identify the natural
distribution and expression pattern of the novel estrogen
receptor GPER among eutopic endometrial cells and
endometriotic cells. The finding that GPER expression
was upregulated in endometriotic cells as compared to
normal endometrial cells may be important for under-
standing the pathogenesis of endometriosis. The differ-
ences in the epithelial GPER expression levels frequency
Table 4 Frequencies of the epithelial expression levels of GPER (nuclear and cytoplasmic) and the classical sex
hormone receptors in different types of endometriosis
Receptor Expression level Ovarian Endometriosis Peritoneal Endometriosis Deep infiltrating Endometriosis p-value
GPER cyt High 14/20 (70.0%) 9/18 (50.0%) 7/22 (31.8%) 0.01
Low 6/20 (30.0%) 9/18 (50.0%) 15/22 (68.2%)
GPER nuc High 16/20 (80.0%) 13/18 (72.2%) 13/22 (59.1%) 0.2
Low 4/20 (20.0%) 5/18 (27.8%) 9/22 (40.9%)
ER-alpha High 18/23 (78.3%) 17/17 (100%) 22/23 (95.7%) 0.02
Low 5/23 (21.7%) 0/17 1/23 (4.3%)
ER-beta High 11/24 (45.8%) 15/17 (88.2%) 9/24 (37.5%) 0.001
Low 13/24 (54.2%) 2/17 (11.8%) 15/24 (62.5%)
PR High 8/21 (38.1%) 16/17 (94.1%) 18/22 (81.8%) <0.001
Low 13/21 (61.9%) 1/17 (5.9%) 4/22 (18.2%)
GPER G protein-coupled estrogen receptor (cyt cytoplasmic, nuc nuclear staining), ER estrogen receptor; PR progesterone receptor. P-Values were calculated by an
exact 2-sided Pearson chi-square test; p≤ 0.05 was considered as statistically significant and is reported in bold type.
Table 5 Frequencies of the stromal expression levels of GPER (nuclear and cytoplasmic) and the classical sex hormone
receptors in different types of endometriosis
Receptor Expression level Ovarian Endometriosis Peritoneal Endometriosis Deep infiltrating Endometriosis p-value
GPER nuc High 27/27 (100%) 19/19 (100%) 28/28 (100%) -
Low 0/27 0/19 0/28
ER-alpha High 25/25 (100%) 18/18 (100%) 25/27 (92.6%) 0.2
Low 0/25 0/18 2/27 (7.4%)
ER-beta High 11/27 (40.7%) 17/18 (94.4%) 7/26 (26.9%) <0.001
Low 16/27 (59.3%) 1/18 (5.6%) 19/26 (73.1%)
PR High 26/26 (100%) 18/19 (94.7%) 26/27 (96.3%) 0.3
Low 0/26 1/19 (5.3%) 1/27 (3.7%)
GPER, G protein-coupled estrogen receptor (nuc nuclear staining); ER estrogen receptor; PR progesterone receptor. No cytoplasmic GPER expression was detected
in the stroma of endometrium and endometriosis. P-Values were calculated by an exact 2-sided Pearson chi-square test; p≤ 0.05 was considered as statistically
significant and is reported in bold type.
Samartzis et al. Reproductive Biology and Endocrinology 2012, 10:30 Page 8 of 9
http://www.rbej.com/content/10/1/30
within the various types of endometriosis, i.e., the more
frequent high cytoplasmic expression levels in epithelial
ovarian endometriotic cells, as well as the differences in
epithelial and stromal expression patterns, appear to
contradict the classification of endometriosis as a
homogenous disease. Finally, the detection of specific
GPER receptor antagonists may provide novel thera-
peutic treatment options for endometriosis.
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